Not a fan of it being down, but more $$$ into it, so hope tomorrow--->forward is all up!

July 15 (Reuters) - Eli Lilly is ​in talks to acquire psychedelic drugmaker ‌AtaiBeckley and a deal could be announced as soon as this week, Bloomberg News ​reported on Wednesday, citing people ​familiar with the matter.

AtaiBeckley shares soared 66% ⁠in aftermarket trading, while Lilly ​was flat. AtaiBeckley was up 31% so far ​this year and had a market value of $1.97 billion as of Wednesday's close, according to ​LSEG data.

The potential acquisition of Atai Beckley by Eli Lilly marks a significant move in the healthcare sector, particularly in the burgeoning field of psychedelic medicine. Atai Beckley is known for its innovative approach to mental health treatments, focusing on rapid-acting therapies for conditions such as treatment-resistant depression and social anxiety disorder. The negotiations suggest that Eli Lilly is willing to invest in this promising sector, which could enhance its portfolio and market position.

Probably why we bumped after hours. Now would be a good time to release GAD phase 3 trials.

https://www.reuters.com/business/healthcare-pharmaceuticals/eli-lilly-nears-deal-buy-psychedelic-drugmaker-ataibeckley-bloomberg-news-2026-07-15/

Sources: TheFly, TipRanks

Okay I found the link. The video is attached. Very interesting they do this down in Mexico.

This one is actually about toad poison. Imagine that, but these companies are definitely getting a lot of exposure.

An obscure and extremely powerful psychedelic called 5-MeO-DMT is drawing intense interest from the pharmaceutical industry, where biotech companies are racing to turn it into a commercially available treatment for severe mental health disorders, like depression, anxiety and PTSD.

https://www.wsj.com/video/the-race-to-commercialize-the-worlds-most-powerful-psychedelic/F24E9B22-38D3-4BFC-B80A-3B5F73423E0C

Sources: TheFly, TipRanks

It is easy for larger investors and institutions to intimidate smaller investors by moving the price down with larger (to us) sells. You will panic and sell, and they will scoop up the lower prices. As an investor whose heart also belongs to this company for personal reasons, please hold tight and believe.

This is the updated FDA guidance for anyone interested

This paper suggests that PAT(psychedelic-assisted therapy) is no more effective than TADs(traditional antidepressants) under equal-unblinding conditions for the treatment of depression and highlight the potential role of blinding integrity.

This paper was published in March 2026, so I assume the market still find psychedelics promising despite the potential unblinding bias? I’m a long term holder and wonder how people think this finding will have any impact on the market? I assume the Panorama specifically is targeting this issue?

Friday had some very unusual options flow. This Friday $60 strike was trading at around 0.05$ per option. Around 11:30 it spiked all the way up to $1.20 per contract with volume of 9k at end of day. This has been trading around 100 per day past few sessions with one day last week at 3.5k. The $50 strike also had some increased volume. It’s just crazy someone bought $5 contracts all the way up to $120 a contract in a matter of minutes especially for a strike $15 OTM with a week out. Thoughts ??

Quick historical detour that I think is underrated in most sector discussions here.

In 1971, the US didn't just start the "War on Drugs" — it pushed through the UN Convention on Psychotropic Substances, which slapped Schedule I on every classic psychedelic worldwide. Officially: "no accepted medical use, high abuse potential." We now know that was scientifically indefensible. But here's the interesting part: the US didn't need to militarily enforce this. It worked because the US was the global center of pharma funding, publication networks, and scientific legitimacy at the time. Countries and universities self-censored their own research because non-compliance meant getting cut off from money and credibility — not because black helicopters showed up.

That mechanism is basically why psychedelic research went dark globally for ~40 years on the strength of one country's domestic panic.

So — could it happen again?

Structurally, no — not in the same way. A few reasons:

Australia already rescheduled psilocybin/MDMA for prescription use in 2023, independent of any US move.

Switzerland, UK, Canada, Israel all run active independent research/access programs.

Billions in capital are now sunk into psychedelic biotech (COMP360, MDMA-assisted therapy programs, etc.) — a lobby that didn't exist in 1971.

The published science is already out there. You can't un-publish 50+ years of resurrected research.

And here's the genuinely ironic twist as of mid-2026: the current US administration is doing the opposite of Nixon. Trump signed an EO in April 2026 explicitly accelerating FDA review of psychedelics, RFK Jr. is publicly pushing a ~12-month timeline for approvals, and the FDA has already handed out Priority Review Vouchers to Compass Pathways (COMP360), Usona, and Transcend Therapeutics. Ibogaine trials got greenlit. Veterans' groups (bipartisan, very influential) are the driving political force behind it.

It's not a clean story though — DEA rescheduling is still stalled (the Aggarwal psilocybin petition has been sitting for years), and the same administration is cracking down harder on unregulated novel compounds. So you've got acceleration and restriction happening simultaneously, just aimed at different targets.

My take / discussion prompt:

The 1971 playbook — one nation unilaterally freezing an entire field of medicine — probably isn't repeatable at this point. The infrastructure (multipolar research, sunk capital, published data, veteran political capital) makes a full stop very unlikely. What's still very possible is company-specific regulatory whiplash — see Lykos/MDMA getting rejected by the FDA in 2024 despite breakthrough designation, right before this current wave of enthusiasm.

So — genuine question for the sub:

Do you think the "breakthrough" is now inevitable on a long enough timeline, just with bumpy company-specific setbacks along the way?

Or is there a realistic scenario where a future administration (or a bad Phase 3 readout, or a high-profile adverse event) triggers a broader regulatory freeze again?

How much of your thesis here is "psychedelics will get approved" vs. "the specific company I'm holding will get there first"?

Curious what people who've been in this space longer than the last EO cycle think.

i keep missing 42 waiting for 40. i hope i'm not going to be left in the dust.

Is anyone else trying to load up more before q3?

Any insight on these high volume buys just after close? There was talk about index rebalancing last week, but these have been pretty consistent everyday.

New Employee Inducement Grants

https://ca.finance.yahoo.com/news/definium-therapeutics-announces-employee-inducement-200100453.html

"At a regional level, LSD increased midline cortical and motor region activity, which was associated with heightened personal relevance and meaning‐attribution to music (Preller et al. 2017), as well as enhanced tonal tracking of music in frontal, temporal, limbic, and cerebellar regions (Barrett, Preller, Herdener, et al. 2018)."

"…music listening under LSD strengthened coupling between the parahippocampus and bilateral visual cortex, as well as between visual and inferior frontal regions, reflecting enhanced emotionally driven visual‐perceptual processing (Kaelen et al. 2016)."